Global Hepatitis Drugs Market to grow at a rapid pace

Hepatitis Drugs Market
Global Hepatitis Drugs Market

Hepatitis is a medical condition where the liver is predominantly affected, which can also affect the digestive system and brain. There are three major types of hepatitis condition – HAV, HBV, and HCV. HCV is a major public health problem that attacks the liver and leads to inflammation. Certain drugs, toxins, heavy alcohol use, bacterial and viral infections can cause hepatitis infection. Hepatitis C infection can bring both acute and chronic hepatitis disease. Approximately, 80% of the patients get chronically infected with Hepatitis C disease. Hepatitis C Virus (HCV) spreads through the blood of an infected individual by the use of shared needles or supplies used to infuse drugs. Vaccines are available only for Hepatitis A and Hepatitis B viruses. Research into the development of a vaccine for Hepatitis C is underway.

Factors such as the rise in injection drug users, increase in awareness, the presence of unmet need, and the anticipated launch of new drugs are expected to drive market growth during the forecast period. The market is witnessing the emerging trend of pediatric combination vaccines, which protect against multiple causative agents and thereby reduce the costs gain in packaging and administering individual vaccines. The markets in India, Brazil, China, and Russia are also expected to grow at a rapid pace during the forecast period as the prevalence of hepatitis in these countries is high.

The major drivers of the hepatitis drugs market include the second generation DAAs of Olysio and Sovaldi. Second generation DAAs are more efficacious and have lesser adverse effects. Currently, the market players are developing IFN therapies for the treatment of Hepatitis C. These therapies are intended to be all-oral regimens. The HCV drugs segment comprised more than 84% of the total market share in 2016. A major focus in this segment is expected to drive the growth of the hepatitis drugs market in the future.

Market Analysis:

The “Global Hepatitis Drugs Market” is estimated to witness a CAGR of 15.0% during the forecast period 2017–2023. The Hepatitis Drugs market is analyzed based on two segments – conditions and regions.

Regional Analysis:

The regions covered in the report are the Americas, Europe, Asia Pacific, and Rest of the World (RoW). The Americas is set to be the leading region for the hepatitis drugs market growth followed by Europe. The Asia Pacific and RoW are set to be the emerging regions. Japan is set to be the most attractive destination and in Africa, the popularity and the usage of various HBV and HCV drugs are expected to increase in the coming years.

Therapeutic Application Analysis:

The most common hepatitis being viral hepatitis can be caused by either of the five hepatotropic viruses, namely Hepatitis A, Hepatitis B, Hepatitis C, Hepatitis D, and Hepatitis E. non-viral hepatitis can be caused by autoimmune diseases, alcohol, few of prescription medications, and toxic substances. Globally, the industry players are focusing significantly on R&D to gain approval for various clinical trials for future HBV and HCV drugs to be commercially available in the market. The advent of interferon-free combination regimens and DAAs is one of the major drivers for the global hepatitis drugs market, specifically for the HCV market. Moreover, various IFN-regimens are under development as all-oral regimens. These therapies are expected to attain higher SVR and cause lesser side effects than currently approved therapies. The market is also witnessing various mergers, acquisitions, and collaborations among the top players, which is defining the future of the Global Hepatitis Drugs market.

Key Players:

Gilead Sciences Inc., Abbvie Inc., Johnson & Johnson, Merck & Co. Inc., GlaxoSmithKline plc, Vertex Pharmaceuticals Inc., Novartis AG, Hoffmann-La Roche Ltd., and other predominate & niche players.

Competitive Analysis:

At present, the HCV drugs are dominating the Global Hepatitis Drugs market – but, a lot of new players are focusing on developing HBV drug molecules to gain future business opportunities. Especially, big players along with the collaboration with other SMBs for clinical trials of hepatitis molecules and compounds are coming with new commercial targeted drugs in the market and they are expecting a double-digit growth in the upcoming years. Significant investments in R&D in this market are expected to increase and collaborations, merger & acquisition activities are expected to continue.

Benefits:

The report provides complete details about the usage and adoption rate of hepatitis drugs in various therapeutic verticals and regions. With that, key stakeholders can know about the major trends, drivers, investments, vertical player’s initiatives, and government initiatives towards the hepatitis drugs adoption in the upcoming years along with the details of commercial drugs available in the market. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.

Category:  Healthcare Market Research

Contact Details:

Aarkstore Enterprise

+917710006788 | contact@aarkstore.com | aarkstore.com

Brain Tumor Diagnosis Market was valued at approx USD 426 Million in 2017

Brain Cancer Diagnostics Report by Material, Application, and Geography-Global Forecast to 2021 is a professional and in-depth research report on the worlds major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, United Kingdom, Japan, South Korea and China).

Global Brain Cancer Diagnostics Market

The report firstly introduced the Brain Cancer Diagnostics basics: definitions, classifications, applications, and market overview; product specifications; manufacturing processes; cost structures, raw materials and so on.

Then it analyzed the worlds main region market conditions, including the product price, profit, capacity, production, supply, demand, and market growth rate and forecast etc. In the end, the report introduced new project SWOT analysis, investment feasibility analysis, and investment return analysis.

Category: Healthcare Market Research

Contact Details:

Aarkstore Enterprise

+91 7710006788 | contact@aarkstore.com | aarkstore.com

Get a glimpse on Insulin Resistance Market!

Insulin Resistance – Global API Manufacturers, Marketed and Phase III Drugs Landscape 2018, the report provides comprehensive insights about marketed and Phase III products for Insulin Resistance. The report includes information on marketed products including their product description, patent details, forecasted sales till 2020 & API manufacturer details by country.

 

Insulin Resistance Market Size
Insulin Resistance Market and Forecast 2020

 

Global API Manufacturers of Marketed Products for Insulin Resistance

Coverage of API manufacturers for Insulin Resistance marketed products spanning across United States, Europe, China, and India. The manufacturers’ details include manufacturers’ name along with their location.

Emerging Phase III products for Insulin Resistance

This report provides a comprehensive understanding of the emerging Phase III therapies for Insulin Resistance which can turn out to be future prospective competitors for the marketed products. It will also put light on the current market trends. Their forecasted global sales are also provided till 2020.

Methodology

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by the DelveInsight team of industry experts.

Secondary information and data have been collected from various printable and non-printable sources like search engines, news websites, government websites, trade journals, white papers, magazines, trade associations, books, industry portals, industry associations, and available databases.

Scope

  • A review of the marketed products for Insulin Resistance including their description, route of synthesis, regulatory milestones, forecasted sales estimates till 2020 and API manufacturer details.
  • Patent information coverage of the marketed products including the patent number, holder, grant and patent expiry details.
  • API manufacturers for the marketed products with location details.
  • Emerging Phase III product profiles for Insulin Resistance including product description, developmental activities, licensors & collaborators and chemical information.

Reasons to Buy

  • API intelligence for marketed drugs for the indication and gaining insights of API manufacturers.
  • Evaluate the marketing status and patent details of products to exploit opportunities for generic drug development.
  • Design effective counter-strategies to gain the competitive advantage by identifying the key patent expiry details and exclusivity with respect to the indication.
  • Establish a comprehensive understanding of the emerging Phase III products which can be future competitors in this space.

Category: Healthcare Market Research

Contact Details:

Aarkstore Enterprise

+91 7710006788 | contact@aarkstore.com | aarkstore.com

Corporate strategy Analysts summarization of Comvita Ltd.

Comvita Ltd (CVT) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations.

Comvita Ltd (CVT) - Financial And Strategic SWOT

The profile contains critical company information including:

– Business description A detailed description of the company’s operations and business divisions.
– Corporate strategy Analysts summarization of the company’s business strategy.
– SWOT Analysis A detailed analysis of the company’s strengths, weakness, opportunities, and threats.
– Company history Progression of key events associated with the company.
– Major products and services A list of major products, services, and brands of the company.
– Key competitors A list of key competitors to the company.
– Key employees A list of the key executives of the company.
– Executive biographies A brief summary of the executive’s employment history.
– Key operational heads A list of personnel heading key departments/functions.
– Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company.
– Key manufacturing facilities A list of key manufacturing facilities of the company.
– Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
– Interim ratios for the last five interim periods The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Comvita Ltd (Comvita) is a healthcare company that provides natural health and beauty products.
Its product categories include healthcare, functional foods, personal care and medical. The company’s product portfolio includes bee pollen, apple cider vinegar, antioxidants, colostrum, herbal extracts, honey, Manuka honey, olive leaf complex, nutritional oil, royal jelly, skincare, winter wellness, and wound care products.

The company operates manufacturing facilities in New Zealand, Hong Kong, Taiwan, Australia, Japan, the UK, and South Korea. In Europe, the company sells its products through health stores and retail chains such as Tesco, Boots, and Sainsbury. It operates through subsidiaries in the US and China. Comvita is headquartered in Te Puke, New Zealand.

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

Understand and respond to your competitors business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Scout for potential investments and acquisition targets, with detailed insight into the companies strategic, financial and operational performance.

Gain key insights into the company for academic or business research.

Category: Healthcare Market Research

Contact Details:

Aarkstore Enterprise
+91 7710006788 | contact@aarkstore.com | aarkstore.com

Effective Microorganisms effect on the ecosystem.

EM Bacteria Report by Material, Application, and Geography-Global Forecast to 2022 is a professional and in-depth research report on the worlds major regional market conditions, focusing on the main regions (North America, Europe and Asia-Pacific) and the main countries (United States, Germany, United Kingdom, Japan, South Korea and China).

EM Bacteria Market

The report firstly introduced the EM Bacteria basics:

Definitions, classifications, applications, and market overview; product specifications; manufacturing processes; cost structures, raw materials and so on. Then it analyzed the worlds main region market conditions, including the product price, profit, capacity, production, supply, demand, and market growth rate and forecast etc. In the end, the report introduced new project SWOT analysis, investment feasibility analysis, and investment return analysis.

The report includes six parts, dealing with:

1.) Basic Information
2.) Asia EM Bacteria Market
3.) North American EM Bacteria Market
4.) European EM Bacteria Market
5.) Market Entry and Investment Feasibility
6.) Report Conclusion.

Part I EM Bacteria Industry Overview
Chapter One EM Bacteria Industry Overview
Chapter Two EM Bacteria Up and Down Stream Industry Analysis

Part II Asia EM Bacteria Industry (The Report Company Including The Below Listed But Not All) 
Chapter Three Asia EM Bacteria Market Analysis
Chapter Four 2013-2018 Asia EM Bacteria Productions Supply Sales Demand Market Status and Forecast
Chapter Five Asia EM Bacteria Key Manufacturers Analysis
Chapter Six Asia EM Bacteria Industry Development Trend

Part III North American EM Bacteria Industry (The Report Company Including The Below Listed But Not All)
Chapter Seven North American EM Bacteria Market Analysis
Chapter Eight 2013-2018 North American EM Bacteria Productions Supply Sales Demand Market Status and Forecast
Chapter Nine North American EM Bacteria Key Manufacturers Analysis
Chapter Ten North American EM Bacteria Industry Development Trend

Part IV Europe EM Bacteria Industry Analysis (The Report Company Including The Below Listed But Not All)
Chapter Eleven Europe EM Bacteria Market Analysis
Chapter Twelve 2013-2018 Europe EM Bacteria Productions Supply Sales Demand Market Status and Forecast
Chapter Thirteen Europe EM Bacteria Key Manufacturers Analysis
Chapter Fourteen Europe EM Bacteria Industry Development Trend

Part V EM Bacteria Marketing Channels and Investment Feasibility
Chapter Fifteen EM Bacteria Marketing Channels Development Proposals Analysis
Chapter Sixteen Development Environmental Analysis
Chapter Seventeen EM Bacteria New Project Investment Feasibility Analysis

Category:  Healthcare Market Research

Contact Details:

Aarkstore Enterprise

+917710006788 | contact@aarkstore.com | aarkstore.com

 

Diabetic Peripheral Neuropathy, on a research ground!

Diabetic Peripheral Neuropathy – Pipeline Insights, 2017

The report provides comprehensive insights into the ongoing therapeutic research and development across Diabetic Peripheral Neuropathy. The report provides a complete understanding of the pipeline activities covering all clinical, pre-clinical and discovery stage products. A comparative pipeline therapeutics assessment of Diabetic Peripheral Neuropathy by development stage, therapy type, route of administration and molecule type is also covered in the report. It also has a special feature on the inactive pipeline products in this area.

 

Pipeline Insights - Diabetic Peripheral Neuropathy
Diabetic Peripheral Neuropathy Pipeline Insights

 

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

Scope of the report

  • The report provides a snapshot of the pipeline development for the Diabetic Peripheral Neuropathy.
  • The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the Diabetic Peripheral Neuropathy.
  • The report provides pipeline product profiles which include product description, developmental activities, licensors & collaborators and chemical information.
  • Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Diabetic Peripheral Neuropathy.

The report also covers the dormant and discontinued pipeline projects related to the Diabetic Peripheral Neuropathy.

Reasons to Buy

  • Establish a comprehensive understanding of the pipeline activity across this Diabetic Peripheral Neuropathy to formulate effective R&D strategies.
  • Gather information of the emerging competitors having a potentially lucrative portfolio in this space and create effective counter-strategies to gain competitive advantage.
  • Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.
  • Plot corrective measures for pipeline projects by understanding the pipeline depth and focus of Diabetic Peripheral Neuropathy Therapeutics.
  • Devise in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying inactive projects and understanding the factors that might have halted their progress.

Category: Healthcare Market Research

Contact Details:

Aarkstore Enterprise
+91 7710006788 | contact@aarkstore.com | aarkstore.com

Hepatitis D, an Overview !

Hepatitis D-Pipeline Insights, 2017, the report provides comprehensive insights of the ongoing therapeutic research and development across Hepatitis D. The report provides a complete understanding of the pipeline activities covering all clinical, pre-clinical and discovery stage products. A comparative pipeline therapeutics assessment of Hepatitis D by development stage, therapy type, route of administration and molecule type is also covered in the report. It also has a special feature on the inactive pipeline products in this area.

 

Hepatitis D Pipeline Insight
Hepatitis D Pipeline Insight | Research and Reports

 

The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts. Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.

The scope of the report

• The report provides a snapshot of the pipeline development for the Hepatitis D
• The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the Hepatitis D
• The report provides pipeline product profiles which include product description, developmental activities, licensors & collaborators and chemical information
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Hepatitis D
• The report also covers the dormant and discontinued pipeline projects related to the Hepatitis D

Reasons to Buy

• Establish a comprehensive understanding of the pipeline activity across this Hepatitis D to formulate effective R&D strategies
• Gather information of the emerging competitors having a potentially lucrative portfolio in this space and create effective counter-strategies to gain competitive advantage
• Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine
• Plot corrective measures for pipeline projects by understanding the pipeline depth and focus of Hepatitis D therapeutics
• Devise in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying inactive projects and understanding the factors that might have halted their progress

Category: Healthcare Market Research

Contact Details:

Aarkstore Enterprise

+91 7710006788 | contact@aarkstore.com | aarkstore.com

Breast augmentation, a cosmetic miracle.

Breast augmentation is one of the most popular cosmetic surgical procedures worldwide. The breast implants market is expected to grow at a steady pace driven by the popularity of breast augmentation procedures, rise in the disposable income of women.

Breast Implants Market

Long–term Outlook: The global breast implants market, has witnessed a steady growth and is anticipated to grow with a healthy CAGR during the forecast period.

Breast Implants Market: Segment wise Outlook

The silicone breast implants segment is expected to grow at fast pace because of the popularity of highly cohesive silicone implants made of high strength silicone gel and textured with silicone shell. Silicone is the most preferred breast implants worldwide. It accounted for more than 80% market share in 2015.

Breast Implants Market: Region wise Outlook

The breast implants market in APAC is expected to grow at a faster pace than the market in the Americas because of the high acceptance of the procedure in China and South Korea.  It is likely that the Americas will lead the breast implants market with more than 60% market share by the year 2022.

The report covers in-depth analysis on:
Breast Implants Market Segments
Breast Implants Market Dynamics
Historical Actual Market Size, 2014-2015
Market Size & Forecast 2016 to 2022
Competition & Companies involved
Market Growth Drivers and Challenges

Breast Implants Market – By Segment

  • Silicone Breast Implants
    Saline Breast Implants

Breast Implants Market: By Geography
• The Americas
• United States
• Rest of the Americas
• Europe, Middle East, & Africa (EMEA)
• Asia Pacific(APAC)

Key Companies Analysis
• Allergan
• GC Aesthetics
• Mentor Worldwide LLC
• Sientra
• Arion Laboratories
• Establishment Labs

About Aarkstore Enterprise

Aarkstore curates global market research reports from various industry verticals and serves businesses worldwide. As market research report resellers, we at Aarkstore, partner with established publishers for both; syndicated data and customized reports. The market research data supplied by us is up-to-date and reliable for current day industry analysis and future market forecasts equally.

Avail market research reports from us and gathers critical information about customer preferences, market requirements, key drivers and challenges for your business to align your strategies with them. The comprehensive overview of the market provided will allow you to make insight-driven decisions giving you an upper hand in the competitive landscape

Category of Report:- Healthcare Market Research Reports

For more inquiry contact our sales team at contact@aarkstore.com

Contact Details:
Aarkstore Enterprise
24/7 Online Support:
+91 9987295242

In Vitro Fertilization IVF in Growth!

In-vitro fertilization (IVF) has become an established treatment option for different forms of infertility. IVF procedures help infertile people to conceive. IVF provides women the opportunity to become pregnant using her own eggs or donor’s eggs and sperm from her partner or from a sperm donor. As the IVF procedure is quite expensive, people generally try out other options. In case of failure in other treatments, IVF remains as the only option for the people longing to experience parenthood. Additionally, in certain cases, IVF is chosen if the parents are fearful of passing certain genetic disorders to the child. The embryos can be tested for genetic abnormalities in medical labs prior to implantation.

In vitro fertilization Market Reports
In Vitro Fertilization IVF Market Research

 

The factors such as the rise in the rate of infertility and surrogacy in developing countries, increasing occurrence of reproductive tourism, and high success rate of IVF are anticipated to be the drivers for the growth of the market. Additionally, the changing lifestyle in urban areas and increased age of parenthood are expected to boost the growth of the market. Despite the drivers, the high cost related to assisted reproductive techniques (ART) may hamper the growth of the global in-vitro fertilization market.

IVF Market Segmentation:

  • The global in-vitro fertilization market has been segmented based on product, type, end-user, and region.
  • Based on the product, the market is segmented into devices and reagents. The devices segment is further segmented into imaging systems, sperm separation system, ovum aspiration pump, cerosystem, and the micromanipulator. The reagent segment is segmented into embryo culture media, cryopreservation media, sperm processing media, and ovum processing media.
  • Based on the type, the market is segmented into intrauterine insemination (IUI), in-vitro fertilization (IVF), intracytoplasmic sperm injection (ICSI), and IVF using donor eggs.
  • Based on end-user, the market is segmented into fertility clinics, hospitals, clinical research centers, and others.

The global in-vitro fertilization market is expected to register a CAGR of 10.50% during the forecast period from 2018 to 2023.

Study objectives:

  • To provide a detailed analysis of the market structure along with the forecast of various segments and sub-segments of the in-vitro fertilization market.
  • To provide insights into factors affecting the market growth.
  • To analyze the global in-vitro fertilization market based on various tools such as supply chain analysis and Porter’s five force analysis.
  • To provide historical and forecast revenue of market segments and sub-segments with respect to regions and their respective key countries.
  • To provide country-level analysis of the market with respect to the current market size and future perspective.
  • To provide country-level analysis of the market for segments by product, type, end-user, and region.
  • To provide strategic profiling of key players in the market, comprehensively analyzing their core competencies and drawing a competitive landscape for the market.
  • To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the in-vitro fertilization market.

Target Audience:

  • IVF device manufacturers & suppliers
  • Biotechnology companies
  • Fertility clinics
  • Hospitals & clinics
  • Academic research institutes
  • Government institutes

Key Findings:

  • The global in-vitro fertilization market is expected to register a CAGR of 10.50% during the forecast period from 2018 to 2023.
  • Based on the product, the devices segment accounted for the largest market share of 53.5% in 2017, with a market value of USD 3,739.7 million in 2017.
  • Based on the type, the intrauterine insemination (IUI) segment accounted for the largest market share of 35.4% in 2017, with a market value of USD 2,470.3 million.
  • Europe holds the largest share of the global in-vitro fertilization market which is expected to reach USD 5,074.1 million by 2023.
  • Asia-Pacific is the fastest growing market, which is expected to register a CAGR of 11.05 % from 2018 to 2023.

Regional Analysis: US, Canada, South America, Germany, France, UK, Italy, Spain, Japan, China, India, Australia, South Korea,

Category: Healthcare Market Research

Contact Details:

Aarkstore Enterprise
+91 7710006788 | contact@aarkstore.com | aarkstore.com

Medicines Regenerating Tissues

Regenerative medicine is an interdisciplinary field that applies life science and engineering principles for the regeneration or repair of injured/diseased tissues or organs resulting from various causes including, disease, defects, trauma and aging. The field includes the generation and use of tissue engineering, therapeutic stem cells and the production of artificial organs. It also allows scientists to grow organs or tissues in the lab and implant them in the body safely when the body fails to heal itself. Notably, it has great potential to solve the problem of organ shortage. According to the estimation of World Health Organization, there is an increasing prevalence of diabetes among adults over the age of 18 years, that has increased to 8.5% in 2014 compared to 4.5% in 1980 across the globe. As per the estimation of Arthritis Foundation, the number of people expected to be diagnosed from arthritis will be more than 78 million, by 2040.

Global Regenerative Medicine Market 2024
Global Regenerative Medicine Market

The market for regenerative medicine is driven by increasing prevalence of neuronal disease, cancer and genetic disease, emerging application of regenerative medicine, and advancement in technology. Huge number of ongoing clinical trails and strong product pipeline are providing market growth oppurtunity. High cost of the treatment, regulatory issues and ethical issuesare hampering the market growth.

Market Analysis:
The “Global Regenerative Medicine market” is estimated to witness a CAGR of 16.6% during the forecast period 2018–2024. The global market is analyzed based on three segments – Therapy, Application and regions.

Regional Analysis:
The regions covered in the report are the North America, Europe, Asia Pacific, and Rest of the World (ROW). North America is the major shareholder in the global regenerative medicine market, followed by Europe. Asia-Pacific region is expected to have the fastest growth rate with the market growth centered at Japan, China and India. This is mainly due to increasing funding in healthcare research, rising research activities, growing patient pool, flexible regulatory environment for clinical trials, and rising healthcare expenditure.

Therapy Analysis:
Immunotherapy occupied major market share of global regenerative medicine market in 2017, and is expected to remain same during the forecasted period. Increasing product approvals, emerging technological advancements in cell and gene therapy, flexible regulatory for stem cell based research, and growing awareness regarding the benefits of stem cell therapies.

Application Analysis:
The market by application is segmented into cancer, central nervous system, orthopedic and musculoskeletal, diabetes, dermatology, cardiovascular and others. Among various application, dermatology occupied the largest share in 2017 and cancer segment is expected to grow at fastest rate during the forecasted period. Growing aging population, changing lifestyle, increasing disease prevalence makes cancer, the fastest growing application segment during the forecasted period.

Key Players:
Allergan plc, Integra lifesciences, Mimedx Group, Inc., Medtronic plc, Organogenesis Inc., Zimmer Biomet, Acelity L.P. Inc., Nuvasive, Inc., Stryker Corporation, Japan Tissue Engineering Co., Ltd. (Fujifilm Holdings Corporation subsidiary), Osiris Therapeutics, Inc., Vericel Corporation and other predominate and niche players.

Competitive Analysis:
Currently dermatology segment dominates the global regenerative medicine segment. A lot of researches are going on cancer, CNS, cardiovascular, orthopedic & musculoskeletal applications. The increasing importance of regenerative medicine has resulted in the launch of new products and also increased acquisition, approvals, funding to develop new product. For instance, in August 2017, Tissue Regenix Group plc completed the acquisition of acquisition of CellRight Technologies, an US based specialist in regenerative osteoinductive bone scaffolds. In April 2018, Roche acquired a program named Inception 5, focused on regenerative therapies for multiple sclerosis. In May 2018, Novartis received second FDA approval for Kymriah, CAR-T cell therapy for B-cell acute lymphoblastic leukemia (ALL).

Category : Healthcare Market Reports

Contact Details:

Aarkstore Enterprise

+91 7710006788 | contact@aarkstore.com | aarkstore.com